Show simple item record

dc.contributor.authorJacob, Dolly
dc.contributor.authorTomlins, Paul
dc.contributor.authorTaylor, M. Joan
dc.contributor.authorSahota, T. S.
dc.date.accessioned2019-11-12T11:31:11Z
dc.date.available2019-11-12T11:31:11Z
dc.date.issued2019-11-09
dc.identifier.citationJacob, D., Tomlins, P., Sahota, T.S., Taylor, M.J. (2019) Insulin Solution Stability and Biocompatibility with Materials Used for an Implantable Insulin Delivery Device Using Reverse Phase HPLC Methods. Applied Sciences, 9, 4794.en
dc.identifier.urihttps://dora.dmu.ac.uk/handle/2086/18772
dc.descriptionopen access articleen
dc.description.abstractAbstract: Insulin (Humulin® R IU500) has been delivered from an implantable artificial pancreas in diabetic rats and pigs. The artificial pancreas which was implanted in the peritoneum was fabricated from several biocompatible materials such as polycarbonate, stainless steel, polyurethane, titanium and a polyurethane resin. The device also contains a glucose responsive smart gel which controls the di usion of insulin dependent on the surrounding glucose environment. As the insulin reservoir is refillable and in contact with the device materials, assessing its biocompatibility with these various device component materials was conducted. Insulin can undergo chemical degradation mainly via a deamidation reaction on glutamine and asparagine residues rendering its biological hormone functionality. Two Reverse Phase High Performance Liquid Chromatography (RP-HPLC) methods were developed and validated for detection of insulin and degradant Asn A21 desamido insulin (method A) and insulin and degradant Asn B3 desamido insulin (method B). Material biocompatibility studies show that stainless steel and titanium are suitable for an implantable insulin delivery device design over a 31-day period. The use of polycarbonate and polyurethane could be considered if the insulin reservoir in the device was only to remain in the device for less than 11 days after which time there is a loss in cresol which acts in a protective capacity for insulin stability.en
dc.language.isoenen
dc.publisherMDPIen
dc.subjectreverse phase HPLC,en
dc.subjectrecombinant human insulinen
dc.subjectvalidationen
dc.subjectdesamido insulinen
dc.subjectinsulin stabilityen
dc.subjectHumulin Ren
dc.titleInsulin Solution Stability and Biocompatibility with Materials Used for an Implantable Insulin Delivery Device Using Reverse Phase HPLC Methodsen
dc.typeArticleen
dc.identifier.doihttps://doi.org/10.3390/app9224794
dc.peerreviewedYesen
dc.funderOther external funder (please detail below)en
dc.cclicenceCC-BY-NCen
dc.date.acceptance2019-11-05
dc.researchinstituteLeicester Institute for Pharmaceutical Innovation - From Molecules to Practice (LIPI)en
dc.funder.otherThe Edith Murphy Foundationen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record